Latest filing published 28 May 2024 for Nexien Biopharma, INC..
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Evan L. Wasoff: trading record in brief
This profile gathers the share dealings of Evan L. Wasoff in Nexien Biopharma, Inc., where the filings describe the role as finance chief. Between 29 November 2017 and 23 May 2024, the trades on record add up to 12 filings.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
The record was last updated on 28 May 2024 with a share grant in Nexien Biopharma, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 5 days. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Evan L. Wasoff
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 2,000,000 sharesCommon stockSEC:0001214659-24-010004:0
- 250,000 sharesCommon stockSEC:0001214659-23-014443:0
- 250,000 sharesCommon stockSEC:0001214659-23-010399:0
- 250,000 sharesCommon stockSEC:0001214659-23-005671:0
- 250,000 sharesCommon stockSEC:0001214659-23-000679:0
- 250,000 sharesCommon stockSEC:0001214659-22-012390:0
- 250,000 sharesCommon stockSEC:0001214659-22-011124:0
- 250,000 sharesCommon stockSEC:0001214659-22-001419:0
- 500,000 sharesCommon stockSEC:0001214659-21-012344:0
9 of 9 declarations